Cash-strapped Reg­u­lus braces for dras­tic down­siz­ing while hit­ting the brakes on lead pro­grams

Still suf­fer­ing from fi­nan­cial woes trig­gered by a streak of set­backs over the past two years, Reg­u­lus Ther­a­peu­tics is now putting its two clin­i­cal pro­grams …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER